A Phase 2 Randomized Double-Blind Placebo-Controlled Multicenter Study of Efficacy and Safety of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer That Is Estrogen or Progesterone Receptor-Positive and HER2-Normal

K
Kathy Miller, MD

Primary Investigator

J
Jessica MacLean

Primary Investigator

Overview

The purpose of this study is to determine if enzalutamide and exemestane taken together are better at slowing the growth of breast cancer than exemestane alone.

Description

The purpose of this study is to determine if enzalutamide and exemestane taken together are better at slowing the growth of breast cancer than exemestane alone.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    breast cancer
  • Age: Between 18 Years - 100 Years
  • Gender: Female
Updated on 20 Nov 2022. Study ID: 1311856099

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center